To confirm that CTLs induced with AMACR peptides could exert cytotoxicity against AMACR-expressing prostate cancer cell lines in an HLA-A*2402-restricted manner, we examined their cytotoxic activity against prostate cancer cell lines that express endogenous AMACR by 51Cr-release assay. The gene discussed is AMACR; the disease is prostate carcinoma.